Navigation path

Pharmaceuticals - Union Register

  

Register of orphan medicinal products


GRANTED  

Product information

2-methyl-1-[(4-[6-(trifluoromethyl)pyridin-2-yl]-6-{[2-(trifluoromethyl)pyridin-4-yl]amino}-1,3,5-triazin-2-yl)amino]propan-2-ol methanesulfonate

EU orphan designation number: EU/3/16/1640   
Active ingredient: 2-methyl-1-[(4-[6-(trifluoromethyl)pyridin-2-yl]-6-{[2-(trifluoromethyl)pyridin-4-yl]amino}-1,3,5-triazin-2-yl)amino]propan-2-ol methanesulfonate
Indication: Treatment of acute myeloid leukaemia
Sponsor: Celgene Europe B.V.
Winthontlaan 6 N, 3526 KV Utrecht, Nederland

   Public summary of scientific opinion    

European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
3/05/2016 Orphan designation EMA/OD/253/15 (2016)2742 of 28/04/2016
22/10/2018 Transfer of orphan designation EMA/OD/253/15/T/01 (2018)6989 of 18/10/2018